STE - Educational Analysis * US Equities
Educational Analysis * US Equities

STE

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerSTE
CategoryEducational primer
Last reviewedNovember 10, 2026
You're viewing an older edition of this page.Read the latest edition →

Business Profile & Competitive Position

STERIS plc is a Healthcare company in the Medical – Specialties industry. Its business is built around infection prevention and patient care, selling consumables such as detergents, endoscopy accessories, instruments, and barrier products; capital equipment such as sterilizers, surgical tables, and automated endoscope reprocessors; and services that include equipment installation and maintenance, instrument and scope repair, laboratory testing, microbial reduction, outsourced reprocessing, and operating-room connectivity solutions. The company reports through three segments—Healthcare, Applied Sterilization Technologies, and Life Sciences—after divesting its Dental segment in fiscal 2025, which is now treated as discontinued operations.

The numbers supporting STERIS’s competitive position are reasonably solid. The company carries a 13.4% net margin and an 11.5% ROE, which suggest it can convert revenue into profit and generate a respectable return on shareholder equity for a regulated medical-products business. A beta of 0.86 also points to lower stock volatility than the broader market. Additional supporting facts from the company’s own disclosures include no single customer making up more than 10% of revenue in Healthcare, AST, or Life Sciences; no FDA or other regulatory enforcement actions in fiscal 2026; and zero products in the FDA MedWatch Safety Alerts database with no Class I recalls in fiscal 2026, 2025, or 2024. Its capital-equipment backlog grew to $490.7 million at March 31, 2026, from $452.9 million at March 31, 2025. Together, these figures paint a picture of a stable, diversified medical-specialty franchise rather than a speculative growth story.

Financial Posture

As of the current snapshot, STERIS trades at roughly $256.94, giving the company a market capitalization of $25.1 billion and a trailing P/E of 30.4. That valuation sits well above the company’s 50-day exponential moving average of $226.38, and the RSI is 75.4, which is on the elevated side of the momentum scale. The 13.4% net margin and 11.5% ROE show profitability, but the P/E of 30.4 also means the market is pricing in a meaningful growth and quality premium relative to those returns. A beta of 0.86 indicates the stock has historically moved less dramatically than the overall market, so the current gap between price and the 50-day EMA, combined with the RSI reading, is a technical observation rather than an intrinsic-value judgment.

Strategic Priorities & Outlook

Steris’s most recent 10-K outlines four concrete operational priorities. First, the company intends to keep expanding irradiation processing capacity using accelerator-based technologies, a move that directly addresses potential cobalt-60 supply risk in the Applied Sterilization Technologies segment. Second, management is applying Lean and continuous-improvement principles across manufacturing, service operations, back office, and support functions. Third, acquisitions remain a stated part of long-term growth strategy. Fourth, Steris has committed to near-term company-wide emissions reductions and is preparing disclosures aligned with CSRD/ESRS and TCFD ESG frameworks. Those priorities suggest management is focused on supply security, margin discipline, bolt-on growth, and regulatory-ready sustainability reporting.

Macro & Geopolitical Exposure

Because STERIS sits in Healthcare / Medical – Specialties, its inherent macro exposure differs from cyclical industrials or commodity producers. The key external variables include FDA regulation and product safety standards, reimbursement trends that affect hospital capital budgets, and procedure volumes that drive demand for consumables and sterilization services. Trade policy and tariffs can matter for the sourcing and placement of capital equipment, while currency fluctuations affect overseas revenue. Supply-chain logistics are relevant, especially given the company’s reliance on cobalt-60 for some sterilization processes and its explicit push toward accelerator-based alternatives. In addition, evolving ESG disclosure rules, including Europe’s CSRD/ESRS and TCFD-aligned climate reporting, are becoming part of the compliance landscape for global healthcare suppliers of this scale.

Recent Developments

The most recent news flow centers on STERIS’s November 2027 fiscal second-quarter results. On November 5, 2026, Zacks reported that STE stock gained after a Q2 earnings and revenue beat, with the company raising its fiscal 2027 EPS guidance. The same day, Seeking Alpha published the Q2 2027 earnings call transcript, and MarketBeat recapped what STERIS said on the call on November 7, 2026. On November 9, 2026, Defenseworld.net noted that CenterBook Partners LP had purchased shares of STERIS. These items indicate that institutional attention has picked up around the recent earnings release and management’s updated fiscal-year outlook.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, STERIS has beaten earnings estimates five times, or 71% of the time, with an average earnings surprise of 3.3%. The average five-day post-earnings move across those quarters is -0.25%, which is classified as a flat drift. That headline average masks some meaningful individual outcomes. The most recent report, on November 4, 2026, delivered EPS of $2.94 versus an estimate of $2.68, a 9.7% surprise that beat expectations; the stock rose 2.5% the next day and was essentially flat over the following five days. On August 5, 2026, EPS came in at $2.59 against a $2.49 estimate, a 4.0% beat, yet the stock slipped 0.4% the next day before rising 1.67% over the next five sessions. On May 11, 2026, EPS of $2.83 missed the $2.85 estimate by 0.7%, but the stock still climbed 4.46% the next day and 5.46% over the subsequent five days. The February 4, 2026 quarter was exactly in line at $2.53 versus $2.53, but the stock fell 7.74% the next day and 7.87% over the next five days. Looking ahead, the next scheduled earnings date is February 3, 2027, after the market close, with a consensus EPS estimate of $2.80.

Because the post-earnings reaction pattern has been inconsistent, readers may want to review the full institutional verdict and broader analyst sentiment for a deeper dive before drawing their own conclusions about how the market may interpret the upcoming report.

Frequently Asked Questions

What does STERIS actually sell?

STERIS sells infection-prevention and patient-care products and services, including consumables like detergents and endoscopy accessories, capital equipment such as sterilizers and surgical tables, and services including equipment maintenance, instrument repair, laboratory testing, and outsourced reprocessing.

How has STERIS performed versus earnings estimates recently?

Over the last eight quarters STERIS has beaten estimates five times, or 71% of the time, with an average earnings surprise of 3.3%. However, the average five-day post-earnings drift is -0.25%, which is classified as flat.

What strategic priorities has STERIS highlighted in its 10-K?

The company is expanding accelerator-based irradiation capacity to reduce cobalt-60 supply risk, applying Lean principles across operations, pursuing acquisitions as part of long-term growth, and preparing ESG disclosures aligned with CSRD/ESRS and TCFD standards.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 10, 2026
STERIS plc · Healthcare / Medical - Specialties
$25.1BMarket cap
30.4P/E
13.4%Net margin
11.5%ROE
71%Beat rate, last 8Q
3.3%Avg EPS surprise
-0.25%Avg 5-day move after earnings
2027-02-03Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-04$2.94$2.68+9.7%+2.5%null%
2026-08-05$2.59$2.49+4%-0.4%+1.67%
2026-05-11$2.83$2.85-0.7%+4.46%+5.46%
2026-02-04$2.53$2.530%-7.74%-7.87%
2025-11-05$2.47$2.35+5.1%--
2025-08-06$2.34$2.26+3.5%--

Previous STE editions

Beyond the primer

Get the institutional verdict on STE

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the STE verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.